Global Breast Cancer Liquid Biopsy Testing Devices Market 2024-2028
The breast cancer liquid biopsy testing devices market is forecasted to grow by USD 1164 mn during 2023-2028, accelerating at a CAGR of 31.34% during the forecast period. The report on the breast cancer liquid biopsy testing devices market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of breast cancer, increasing preference for non-invasive procedures, and rising number of new product launches and fda approvals.
Technavio's breast cancer liquid biopsy testing devices market is segmented as below:
By Type
- CTCs and circulating nucleic acids
- Extracellular vesicles
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the technological advances as one of the prime reasons driving the breast cancer liquid biopsy testing devices market growth during the next few years. Also, growing emphasis on breast cancer diagnosis and increasing focus on direct-to-customer marketing will lead to sizable demand in the market.
The report on the breast cancer liquid biopsy testing devices market covers the following areas:
- Breast cancer liquid biopsy testing devices market sizing
- Breast cancer liquid biopsy testing devices market forecast
- Breast cancer liquid biopsy testing devices market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading breast cancer liquid biopsy testing devices market vendors that include A. Menarini Industrie Farmaceutiche Riunite Srl, Bio Rad Laboratories Inc., Cell Microsystems Inc., Exact Sciences Corp., F. Hoffmann La Roche Ltd., Guardant Health Inc., Illumina Inc., Isogen Life Science BV, Mesa Laboratories Inc., Myriad Genetics Inc., Natera Inc., NeoGenomics Laboratories Inc., Novogene Co. Ltd., OncoDNA, Pfizer Inc., QIAGEN NV, SAGA Diagnostics AB, Sysmex Corp., and Thermo Fisher Scientific Inc.. Also, the breast cancer liquid biopsy testing devices market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.